Sundrug Co., Ltd. · TSE:9989
Sundrug — FY3/26 Earnings Presentation
24 slides from Sundrug's earnings presentation, May 15, 2026
Slide 1: FY3/26 Results Briefing Presentation
FY3/26 Results Briefing Presentation May 15, 2026 Copyright (C) SUNDRUG CO, LTD. ALL RIGHTS RESERVED.
Slide 2: Contents
Contents ◼ FY3/26 Results Summary ◼ FY3/27 Full-Year Guidance ◼ New Medium-term Business Plan and Management Issues Copyright (C) SUNDRUG CO, LTD. ALL RIGHTS RESERVED. 2
Slide 3: FY3/26 Results Summary
FY3/26 Results Summary Copyright (C) SUNDRUG CO, LTD. ALL RIGHTS RESERVED.
Slide 4: FY3/26 Financial Highlights [Consolidated]
FY3/26 Financial Highlights [Consolidated] FY3/26 results Net sales Ordinary income Store openings ¥842.5 billion ¥46.2 billion 73 stores YoY +5.1% YoY +5.4% Total 1,594 stores Net sales Effect of the refurbishment of existing stores; continued strong performance in the dispensing pharmacy and EC bu
Slide 5: Consolidated Income Statement
Consolidated Income Statement (millions of yen) FY3/25 FY3/26 Results Results Guidance Breakdown Breakdown YoY change Vs. guidance Breakdown Net sales 801,811 100.0% 842,512 100.0% 5.1% -0.9% 850,000 100.0% Gross profit 204,087 25.5% 216,170 25.7% 5.9% -1.4% 219,200 25.8% SG&A expenses 159,591 19.9%
Slide 6: Consolidated Income Statement By Business
Consolidated Income Statement By Business (millions of yen) FY3/25 FY3/26 Drugstore business Results Results Guidance Breakdown Breakdown YoY change Vs. guidance Breakdown Net sales 517,333 100.0% 539,379 100.0% 4.3% -0.9% 544,500 100.0% Gross profit 143,633 27.8% 150,748 27.9% 5.0% -1.8% 153,500 28
Slide 7: Store Openings
Store Openings FY3/25 FY3/26 Openings No. of stores Net increase No. of stores Openings Closures Drugstore business 63 1,124 49 18 +31 1,155 Discount store business 27 418 24 3 +21 439 Total 90 1,542 73 21 +52 1,594 FY3/25 FY3/26 [By area] Openings No. of stores Net increase No. of stores Openings C
Slide 8: Same-Store Sales
Same-Store Sales ◼ Same-store Group performance ⇒ Full-year: +1.2 (1H: +1.6, 2H: +0.8) Same-store sales growth by business (YoY) Drugstore business Discount store business (%) FY3/25 FY3/26 (%) FY3/25 FY3/26 10 10 Increased demand due to a rice shortage in the previous year 7.0 7.5 4.2 4.5 4.7 4.4 5
Slide 9: Net Sales By Category
Net Sales By Category (millions of yen) FY3/25 FY3/26 Drugstore business Results Breakdown Results Breakdown YoY change Health care 143,464 27.7% 144,974 26.9% 1.1% Housekeeping 108,247 20.9% 112,824 20.9% 4.2% Beauty care 150,453 29.1% 156,188 29.0% 3.8% Food 91,654 17.7% 100,242 18.6% 9.4% Other 2
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet FY3/25 FY3/26 (millions of yen) (millions of yen) (millions of yen) Total assets: 444,007 Total assets: 475,505 Current aseets +21,286 (Equity ratio 60.7%) (Equity ratio 60.1%) Cash and cash equivalents +5,567 Accounts receivable +2,336 Liabilities Liabilities Inventories
Slide 11: Consolidated Cash Flows
Consolidated Cash Flows FY3/25 FY3/26 Operating Investing (millions of yen) Operating Investing (millions of yen) cash flows cash flows cash flows cash flows 41,164 -35,373 -32,076 43,297 Financing Financing cash flows cash flows -10,600 -5,653 69,698 64,956 64,956 70,523 Opening balance Closing bal
Slide 12: FY3/27 Full-Year Guidance
FY3/27 Full-Year Guidance Copyright (C) SUNDRUG CO, LTD. ALL RIGHTS RESERVED. 12
Slide 13: FY3/27 Business Plan
FY3/27 Business Plan FY3/27 Full-year guidance Consolidated Net sales ¥876.0 billion <YoY change> +4.0% Operating income ¥48.8 billion <YoY change> +4.2% Drugstore business Discount store business Net sales ¥554.0 billion <YoY change> +2.7% Net sales ¥386.0 billion <YoY change> +6.0% Operating incom
Slide 14: New Medium-term Business Plan and Management Issues
New Medium-term Business Plan and Management Issues Copyright (C) SUNDRUG CO, LTD. ALL RIGHTS RESERVED. 14
Slide 15: Review of the previous Medium-term Business Plan
Review of the previous Medium-term Business Plan * “Group” includes our capital and FY3/26 results business alliance partner Operating Operating No. of Group Net sales Group income Group margin Group stores ¥983.5 billion ¥50.3 billion 5.1% 2,026 stores (5.6% when excluding our capital and business
Slide 16: New Medium-term Business Plan FY2026-2030: Target further growth
New Medium-term Business Plan FY2026-2030 FY2025 (FY3/26) Target further ◼ Group net sales ¥983.5 billion growth ◼ Group operating income ¥50.3 billion New Medium- ◼ Group operating margin 5.1％ ◼ ROE 11.7％ term Business Plan Our vision Aim for top-class earning power in the drugstore and discount st
Slide 17: New Medium-term Business Plan
New Medium-term Business Plan ・Strive for balanced and sustainable growth by utilizing diversified store formats including 5-year station-front, suburban and discount stores, and positioning the EC and dispensing vision pharmacy businesses and PB products as our core ・Aim for top-class earning power
Slide 18: New Medium-term Business Plan: Cash allocation
New Medium-term Business Plan Cash allocation ◼ Progressive dividend policy Cash inflows Cash outflows ◼ Target payout ratio of 50％ M&A Financing Capital investment Shareholder returns ◼ Investment plan for drugstores • Store openings: 60/year • Refurbishments: 85/year ◼ Investment plan for discount
Slide 19: [Business strategy] Store openings
[Business strategy] Store openings ◼ Increase the number of stores ◼ Nationwide network Expanding our store network with formats Maintaining store opening standards while adapted to each region’s characteristics targeting a net growth rate of at least 80% Station-front stores (downtown/shopping area
Slide 20: [Business strategy] EC Business Strategy
[Business strategy] EC Business Strategy ◼ Improve the convenience of our EC services and promote information channel strategies Improve the convenience of our EC services and leverage information channels EC results FY3/26 Leverage information channels EC Sales ¥16,811 million (Breakdown 2.0%) Stre
Slide 21: [Business strategy] Promote the dispensing pharmacy business
[Business strategy] Promote the dispensing pharmacy business ◼ Initiatives to capture dispensing demand in regional communities Expansion driven by community-based strategies and digital transformation (DX) Dispensing results FY3/26 Initiatives to increase the number of prescriptions Prescription 18
Slide 22: [Reinforcement of business base] Improve productivity
◼ Initiatives to further [Reinforcement of business base] Improve productivity improve efficiency Introducing an expiration date management system Labor cost -0.4%, decreased by ¥0.25 billion/year ◼ Change paper-based expiration date management Tablet-based or handheld terminal-based management
Slide 23: Shareholder Return
Shareholder Return ◼ We increased dividends for the 24th consecutive fiscal year in the previous fiscal year. This fiscal year we plan to pay an annual dividend of ¥132, with the aim of increasing for the 25th consecutive year. 48.8％ 48.0% Dividend per share 49.4％ Payout ratio 132.0 yen 45.5% 45.8%
Slide 24: Contact
Contact General Affairs Department, SUNDRUG Co., Ltd. [Address] 1-38-1 Wakamatsu-cho, Fuchu-shi, Tokyo 183-0005 [Phone] 042-369-6211 This document contains information on current business plans, earnings forecasts and projections that constitute forward-looking statements. These forward-looking stat